Ongoing Opportunities

Differentiate cognitive impairment associated with schizophrenia (CIAS) from negative symptoms through improved recognition of the pathophysiology of CIAS
Recognize the heavy burden of disease and ongoing unmet needs in patients with CIAS
Assess how ongoing developments in clinical research and improved perspectives on care pathways may help address current limitations in the clinical management of CIAS

Course Description:
Schizophrenia involves positive symptoms like hallucinations and delusions, negative symptoms such as social withdrawal and reduced motivation, and cognitive impairment. Negative symptoms affect about 40% of patients, while cognitive impairment is seen in up to 80%. Though no approved treatments exist for cognitive impairment, clinicians should not dismiss its impact but instead assess all symptoms and explore management strategies like cognitive remediation.

Provided by The France Foundation

Learn More

Addressing Negative Symptoms and Cognitive Impairment Associated With Schizophrenia: A Focus on Digital Therapeutics

CME | 1.00 Credit

Time to Complete: 1 hour

Released:
Expires: August 22, 2025

Maximum Credits:
1.00 / AMA PRA Category 1 Credit(s)™
1.00 / NCPD Contact Hour
1.00 / AAPA Category 1 Credit(s)™

Learning Objectives:

Differentiate the various symptom domains in schizophrenia with a focus toward the pathophysiology of cognitive impairment and negative symptoms
Recognize the burden and unmet needs in schizophrenia associated with the under-management of cognitive impairment and negative symptoms
Assess how ongoing developments in clinical research in schizophrenia and digital therapeutics may help address current limitations in treating cognitive impairment and negative symptoms

Course Description:
Schizophrenia includes positive symptoms like hallucinations, negative symptoms such as social withdrawal, and cognitive impairment. Negative symptoms affect 40% of patients, while cognitive impairment is seen in up to 80%. Understanding emerging digital therapeutics and new pharmacologic treatments can help clinicians prepare for future approvals and optimize care for those who need it most.

Provided by The France Foundation

Learn More

Recognizing and Confirming Potential ATTR in Your Patients

Time to Complete: 1 hour

Released: January 24, 2025
Expires: August 30, 2025

Learning Objectives:

Identify common diagnostic issues for patients with ATTR
Recognize ATTR genotypes and phenotypes, including typical symptomatology
Discuss multidisciplinary strategies for confirming ATTR diagnosis

Course Description:
This activity will cover early diagnosis and intervention for transthyretin amyloidosis (ATTR), which is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part of clinicians. Therapeutic options are limited, but there are new and emerging agents and emerging indications with which clinicians may not be familiar. Access to specialized care centers is limited for many patients, leading to suboptimal management and disease monitoring. This education fills a significant need for healthcare team education to ensure all patients benefit from best practices in recognizing, diagnosing, and managing amyloidosis.

Provided by The France Foundation

Learn More

Advances in the Diagnosis, Assessment, and Therapeutic Management of Biliary Tract Cancers

CME | 1.00 Credit

Time to Complete: 1 hour

Released: September 27, 2024
Expires: September 26, 2025

Maximum Credits:
1.00 / AMA PRA Category 1 Credit(s)™
1.00 / NCPD Contact Hour
1.00 / AAPA Category 1 CME Credits

Learning Objectives:

Describe the steps for early identification of BTC, including molecular testing
Summarize the role played by the MDM2/p53 pathway in BTC
Recognize the limitations of current treatment strategies for BTC
Evaluate ongoing developments in clinical research that may potentially address the current limitations in the clinical management of BTC

Course Description:
Biliary Tract Cancers (BTCs), including gallbladder cancer and cholangiocarcinoma, are rare yet aggressive, making early diagnosis and treatment a challenge. In 2024, over 12,000 individuals are expected to be diagnosed, with 4,530 estimated deaths. Dive into the complexities of BTC identification and management through engaging case discussions and gain expert insights into the role of the MDM2 and p53 pathway in disease progression. Refine your approach to treating these challenging malignancies!

Provided by The France Foundation

Learn More

Advancements in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Integrating New Evidence and Multidisciplinary Approaches for Optimal Care

CME | CNE | CPE | 1.00 Credit

Time to Complete: 1 hour

Released: October 22, 2024
Expires: October 22, 2025

Maximum Credits:
1.00 / AMA PRA Category 1 Credit^TM
1.00 / ANCC Contact Hour
1.00 / CE for Pharmacists

Learning Objectives:

Evaluate the appropriate use of immunotherapies and their combinations in the first-line treatment of veterans with advanced NSCLC without targetable mutations.
Incorporate the latest evidence from clinical trials into the decision-making process for the treatment of NSCLC to optimize patient outcomes.
Effectively recognize and manage immune-related adverse events in advanced NSCLC through multidisciplinary strategies.

Course Description:
This educational program aims to equip healthcare teams with the latest advancements and critical insights into immunotherapy for advanced non-small cell lung cancer (NSCLC). It will provide healthcare professionals with essential tools to evaluate the efficacy, safety, and clinical effectiveness of these therapies. The course will address practice gaps and educational needs through presentations in NSCLC management and treatment. The program includes challenging cases to help recognize and manage individual patient characteristics effectively. The goal is to enhance strategies for optimizing patient care through expert-led education.

Provided by PleXus Communications

Learn More

A New Era for Hemophilia Treatment: Common Goals, Unique Perspectives

CME | 1.00 Credit

Time to Complete: 1 hour

Released: December 20, 2024
Expires: December 19, 2025

Maximum Credits:
1.00 / AMA PRA Category 1 Credit(s)™
1.00 / NCPD Contact Hour
1.00 / CPE Contact Hour (0.10 CEU)
1.00 / AAPA Category 1 CME Credits

Learning Objectives:

Utilize patient needs and preferences to evaluate potential unmet needs of patients with hemophilia
Compare the clinical profiles of novel and emerging therapies for hemophilia
Assess how new and emerging treatments impact the individualization of treatment for patients with hemophilia

Course Description:
Discover the impact of cutting-edge therapies reshaping hemophilia care! From groundbreaking innovations to real-world patient perspectives, this activity brings together leading hemophilia specialists, a dedicated community-based physician, an experienced hemophilia nurse, and a patient with lived experience to share their unique insights.

Provided by The France Foundation

Learn More

New Therapies Across the Spectrum of Prostate Cancer: What do Urology Nurses and Advanced Practice Providers Need to Know?

CME | CNE | CPE | 1.00 Credit

Time to Complete: 1 hour

Released: January 21, 2025
Expires: January 21, 2026

Maximum Credits:
1.00 / ANCC Contact Hour

Learning Objectives:

Explain the results of key clinical trials that demonstrate the efficacy and safety of new and emerging agents for the treatment of advanced PC.
Devise strategies to optimize therapy for PC for individual patients in the community urology setting.
Discuss the roles of nurses and advanced practice providers in improving PC management in the community urology setting.

Course Description:
This program provides healthcare professionals with the latest insights into advanced prostate cancer management to enhance patient care. It equips nurses and advanced practice providers with the tools to critically evaluate the efficacy, safety, and clinical application of new and emerging therapies. Participants will learn strategies for personalizing treatment using biomarkers and clinical factors, including intensification approaches for nonmetastatic and metastatic disease. The program also explores the roles of the healthcare team in improving patient outcomes in community urology settings. This will prepare participants to integrate evidence-based therapies and strategies into practice to improve survival and quality of life for prostate cancer patients.

Provided by PleXus Communications

Learn More

Hybrid Community/VHA Oncology Forums: EGFR Exons 19 and 21 Alterations in Non-Small Cell Lung Cancer: Recent Therapeutic Advances and Implications for Care

CME | CNE | CPE | 1.00 Credit

Time to Complete: 1 hour

Released: January 22, 2025
Expires: January 22, 2026

Maximum Credits:
1.00 / AMA PRA Category 1 Credit^TM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists

Learning Objectives:

Explain current testing types, strategies, and recommendations for molecular testing of patients with NSCLC and how they inform treatment decision-making for patients with EGFR alterations, particularly exon 19 and 21
Survey recent trial data regarding the safety and efficacy data of targeted therapies and combinations for NSCLC patients with EGFR exon 19 and 21 alterations
Outline optimal treatment plans in both the adjuvant and advanced settings for NSCLC patients with EGFR exon 19 and 21 alterations and approaches to effectively communicate treatment goals and considerations with patients
Appraising strategies to identify and mitigate TRAEs associated with anti-EGFR targeted therapies within MDC teams

Course Description:
This program offers comprehensive education for oncology and lung cancer MDC teams on managing NSCLC with EGFR exon 19 and 21 alterations. It covers molecular testing strategies, recent trial data on targeted therapies, and optimal treatment plans in adjuvant and advanced settings. Participants will learn to communicate effectively with patients about treatment goals and address treatment-related adverse events (TRAEs). The curriculum emphasizes patient-centered care, interdisciplinary collaboration, and lifelong learning for improved outcomes. By addressing practice gaps, the program equips healthcare teams with essential tools for evidence-based decision-making and safer, more effective care.

Provided by PleXus Communications

Learn More

PARP Inhibitors for Metastatic Prostate Cancer in the VHA Health System: Integrating New Agents into Practice

CME | CNE | CPE | 1.00 Credit

Time to Complete: 1 hour

Released: February 14, 2025
Expires: February 14, 2026

Maximum Credits:
1.00 / AMA PRA Category 1 Credit^TM
1.00 / CNE Contact Hour
1.00 / CE for Pharmacists

Learning Objectives:

Analyze recent clinical trials and real-world evidence regarding poly-ADP ribose polymerase inhibitors (PARPi) monotherapy and PARPi combinations as therapy for metastatic prostate cancer (mPC).
Summarize the current best practices for applying PARPi based on DNA repair alterations and other biomarkers.
Formulate personalized PARPi-based therapeutic strategies to improve the survival of Veterans with mPC.
Determine how PARPi safety profiles will influence mPC management for individual patients, based on their preferences, comorbidities, prior therapies, and other disease-related considerations.

Course Description:
This program equips clinicians with the knowledge to optimize care for patients with metastatic prostate cancer (mPC) by integrating PARP inhibitors into practice. It explores the latest evidence on genetic testing, biomarker-driven treatment selection, and personalized therapeutic strategies for mPC. Clinicians will learn about indications for PARP inhibitor monotherapy and combination therapies, alongside strategies to manage associated safety concerns. Through a review of recent clinical trials and real-world data, participants will gain insights into improving patient survival and quality of life. By the program's end, attendees will be prepared to apply evidence-based PARP inhibitor therapies.

Provided by PleXus Communications

Learn More